A NEW NP-UPLC METHOD FOR THE SEPARATION AND SIMULTANEOUS QUANTIFICATION OF RAMUCIRUMAB AND ERLOTINIB
DOI:
https://doi.org/10.22159/ijap.2021v13i6.42815Keywords:
Erlotinib, Ramucirumab, Development, Validation, NP-UPLCAbstract
Objective: This investigation demonstrates a stability-indicating and reliable “normal phase ultra-performance liquid chromatography” method to simultaneously quantify Ramucirumab and Erlotinib in the pharmaceutical dosage form.
Methods: Successful separation was accomplished using Chiralcel-OD-3 column (50 mm x 4.6 mm, 3 μm) with an isocratic type of elution using a mobile phase containing n-hexane+isopropyl alcohol+methanol (89:10:1), respectively with 1.0 ml/min flow rate. The wavelength sensor was attuned at 266 nm to quantify Ramucirumab and Erlotinib.
Results: Erlotinib and Ramucirumab peaks were eluted with fine resolution at retention times 1.7807 min and 3.175 min, respectively. In the 10-150 μg/ml and 1-15 μg/ml concentration ranges for Erlotinib and Ramucirumab, the calibration graphs were linear, with regression coefficients of 0.99928 and 0.99976, respectively. The suggested ultra-performance liquid chromatography approach has been shown as sensitive, precise, robust, accurate, specific and stability indicating through the resolution of Erlotinib and Ramucirumab from its degradation-based compounds.
Conclusion: The established ultra-performance liquid chromatography technique was effectively extended to the evaluation of Erlotinib and Ramucirumab in the pharmaceutical dosage form and the test results appeared satisfactory.
Downloads
References
Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer. 2011;128(9):2020-30. doi: 10.1002/ijc.25557, PMID 20635390.
Siegel DL. Recombinant monoclonal antibody technology. Transfus Clin Biol. 2002 Jan;9(1):15-22. doi: 10.1016/s1246-7820(01)00210-5, PMID 11889896.
Ambrosi D, Mollica F. On the mechanics of a growing tumor. Int J Eng Sci. 2002;40(12):1297-316. doi: 10.1016/S0020-7225(02)00014-9.
Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Haick H. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut. 2016;65(3):400-7. doi: 10.1136/gutjnl-2014-308536, PMID 25869737.
Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X, Xiong J. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Mol Cell Biochem. 2014;395(1-2):99-107. doi: 10.1007/s11010-014-2115-2, PMID 24934239.
Lenglinger J, See SF, Beller L, Cosentini E, Asari R, Wrba F, Riegler M, Schoppmann SF. The cardia: esophageal or gastric? Critical reviewing the anatomy and histopathology of the esophagogastric junction. Acta Chir Iugosl. 2012;59(3):15-26. doi: 10.2298/aci1203015l, PMID 23654002.
Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ (clinical research Ed.). 2012;344:e2476.
Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15:71. doi: 10.1186/s12935-015-0221-1, PMID 26180516.
Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst. 2003;95(4):255-7. doi: 10.1093/jnci/95.4.255, PMID 12591977.
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-9. doi: 10.1016/S0140-6736(13)61719-5, PMID 24094768.
Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011;17(16):5257-67. doi: 10.1158/1078-0432.CCR-11-0379, PMID 21712447.
Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A, Delbono O. Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol. 2014;307(1):C25-38. doi: 10.1152/ajpcell.00084.2014, PMID 24788248.
Lee D, Kim D, Choi YB, Kang K, Sung ES, Ahn JH, Goo J, Yeom DH, Jang HS, Moon KD, Lee SH, You WK. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. mAbs. 2016;8(5):892-904. doi: 10.1080/19420862.2016.1171432, PMID 27049350.
Simon GR, Turrisi A, American College of Chest Physicians. Management of small-cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2nd ed. 2007;132(3); Suppl:324S-39S. doi: 10.1378/chest.07-1385, PMID 17873178.
Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2014;(11):CD009948. doi: 10.1002/14651858.CD009948.pub2, PMID 25400254.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322(5):438-44. doi: 10.1001/jama.2019.10232, PMID 31386141.
Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014;20(32):11142-59. doi: 10.3748/wjg.v20.i32.11142, PMID 25170201.
Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, Baldi E. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids. 2004;69(8-9):549-52. doi: 10.1016/j.steroids.2004.05.011, PMID 15288768.
Kim SW, Hayashi M, Lo JF, Yang Y, Yoo JS, Lee JD. ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation. J Biol Chem. 2003;278(4):2661-8. doi: 10.1074/jbc.M205819200, PMID 12446727.
Boyd MA, Menon P, Graves S, Gordon DL. A febrile illness with generalized papular rash involving the palms and soles. Clin Infect Dis. 2007;44(5):704, 755-6. doi: 10.1086/511637, PMID 17278064.
DuPont HL. Acute infectious diarrhea in immunocompetent adults. N Engl J Med. 2014;370(16):1532-40. doi: 10.1056/NEJMra1301069, PMID 24738670.
Pavord ID, Chung KF. Management of chronic cough. Lancet. 2008;371(9621):1375-84. doi: 10.1016/S0140-6736(08)60596-6, PMID 18424326.
Liao M, Sung C, Hung K, Wu C, Lo L, Lu K. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol. 2012;2012:1-12. doi: 10.1155/2012/691369.
Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep. 2016;18(12):61. doi: 10.1007/s11894-016-0535-8, PMID 27747458.
Langell JT, Mulvihill SJ. Gastrointestinal perforation and the acute abdomen. Med Clin North Am. 2008;92(3):599-625, viii. doi: 10.1016/j.mcna.2007.12.004, PMID 18387378.
Alhassan MB, Rabiu M, Agbabiaka IO. O. Interventions for Mooren’s ulcer. Cochrane Database Syst Rev. 2014;1:CD006131. doi: 10.1002/14651858.CD006131.pub3.
Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem. 1993;268(15):11134-42. doi: 10.1016/S0021-9258(18)82102-0, PMID 8098709.
Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood. 1993;82(12):3524-9, PMID 7505115.
Shivani CP, Maheshwari DG. Development and validation of UV spectrometric and HPLC method for estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form. AJPTI. 2016;4:59-70.
Supriya T, Naresh D, Vijaya Kumar G, Haneer MA. Stability indicating RP-HPLC method development and validation for simultaneous estimation of escitalopram and flupentixol pure and marketed formulation. Asian J Pharm Res. 2018;8:4-10.
International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: text and methodology. Vol. Q2(R1); 2005.
Vijayakumari M, Reddy Ch B. Stability indicating validated HPLC method for the determination of zanubrutinib in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res. 2020;13:159-62.
Rajakumari R, Sreenivasa Rao S. Stress degradation studies and development of a validated RP-HPLC method for determination of tiagabine in presence of its degradation products. Int J Pharm Pharm Sci. 2016;8:230-6.
Charu Pandya P, Sadhana Rajput J. Development and validation of stability indicating method RP-HPLC method of acotiamide. Int J Pharm Pharm Sci. 2018;10:1-8.
Athavia BA, Dedania ZR, Dedania RR, Swamy SMV, Prajapati CB. Stability indicating HPLC method for determination of vilazodone hydrochloride. Int J Curr Pharm Sci;9(4). doi: 10.22159/ijcpr.2017v9i4.20975.
Published
How to Cite
Issue
Section
Copyright (c) 2021 SIVA MADHU CHAITANYA, SRINATH NISSANKARARAO, SATYA LAKSHMI GANDHAM
This work is licensed under a Creative Commons Attribution 4.0 International License.
